Precipio, Inc.
- Open
- 23.60
- Day high
- 24.66
- Day low
- 23.10
- Prev close
- 23.68
- Volume
- 108K
- Mkt cap
- $44M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.1
- P/S
- 1.7
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$100K over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions mixed (13F)
Precipio, Inc. (PRPO) is a Healthcare company listed on NASDAQ. The stock is up 70% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
Precipio, Inc. (PRPO) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PRPO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Mar 30, 2026 | — | $0.33 | — | $8M | — |
| Nov 14, 2025 | — | $-0.05 | — | $6M | — |
| Aug 13, 2025 | — | $0.05 | — | $6M | — |
| May 14, 2025 | — | $-0.59 | — | $4M | — |
| Mar 27, 2025 | $0.74 | $-0.23 | -131.1% | $5M | -32.0% |
| Aug 13, 2024 | $-0.05 | $-0.83 | -1560.0% | $4M | +2.6% |
| May 14, 2024 | $-0.93 | $-1.46 | -57.0% | $3M | -20.7% |
| Mar 29, 2024 | $-0.93 | $-0.41 | +55.9% | $4M | -0.7% |
| Nov 13, 2023 | $-1.21 | $-1.04 | +14.0% | $4M | -23.7% |
| Aug 11, 2023 | $-0.10 | $-1.80 | -1700.0% | $4M | +30.9% |
| May 12, 2023 | $-0.13 | $-2.60 | -1900.0% | $3M | +270.7% |
| Nov 10, 2022 | $-0.80 | $-2.80 | -250.0% | $2M | -55.7% |
PRPO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 26, 2026 | SANDBERG RICHARD Adirector | Sell | 900 | $25.02 |
| May 21, 2026 | SANDBERG RICHARD Adirector | Sell | 500 | $25.00 |
| May 21, 2026 | SANDBERG RICHARD Adirector | Sell | 2,034 | $24.89 |
| May 21, 2026 | SANDBERG RICHARD Adirector | Sell | 600 | $24.42 |
| Apr 17, 2026 | Valauri Christina Rizopoulosdirector | Grant | 93 | $29.49 |
| Apr 17, 2026 | Cossman Jeffreydirector | Grant | 365 | $29.49 |
| Apr 17, 2026 | Cohen David Sethdirector | Grant | 445 | $29.49 |
| Apr 10, 2026 | Sabet Ahmed Zakiofficer: Chief Operating Officer | Buy | 19 | $27.93 |
| Jan 20, 2026 | Sabet Ahmed Zakiofficer: Chief Operating Officer | Buy | 31 | $16.30 |
| Jan 20, 2026 | ANDREWS RONALD ASBURYdirector | Grant | 568 | $17.58 |
| Jan 20, 2026 | Cossman Jeffreydirector | Grant | 597 | $17.58 |
| Jan 20, 2026 | Sabet Ahmed Zakiofficer: Chief Operating Officer | Buy | 20 | $23.40 |
| Jan 20, 2026 | Cohen David Sethdirector | Grant | 546 | $24.00 |
| Jan 20, 2026 | Cossman Jeffreydirector | Grant | 437 | $24.00 |
| Jan 20, 2026 | Cohen David Sethdirector | Grant | 746 | $17.58 |
Source: PRPO SEC Form 4 filings, latest May 26, 2026. For informational purposes only — not investment advice.
See the full PRPO insider & 13F page →Precipio, Inc. company profile
Overview
Precipio, Inc. (NASDAQ:PRPO) is a healthcare solutions company founded in 2017 and based in New Haven, Connecticut. The company specializes in diagnostic products, reagents, and services focused primarily on blood cancer testing and hematological diagnostics. Since going public in June 2017, Precipio has evolved from a struggling startup into a company approaching profitability, having achieved positive cash flow and EBITDA in recent quarters. The company operates through two main divisions: a pathology services business that provides diagnostic testing services, and a products division that develops and sells proprietary diagnostic technologies and reagents to laboratories and healthcare providers.
Business
Precipio operates in the medical diagnostics industry, specifically focusing on hematology and blood cancer diagnostics. The healthcare diagnostics market involves the development and provision of tests, technologies, and services that help physicians diagnose diseases, monitor patient health, and guide treatment decisions. This is a critical component of modern healthcare, as accurate and timely diagnosis is essential for effective patient care. The company's core offerings center around blood cancer diagnostics, which involves testing blood, bone marrow, and other specimens to detect various types of blood cancers such as leukemia, lymphoma, and myeloma. These cancers affect the blood-forming tissues and require specialized testing techniques to identify specific genetic markers, cell types, and disease characteristics that guide treatment decisions. **Pathology Services Division** (approximately 75-80% of revenue): This division provides comprehensive diagnostic blood cancer testing services directly to healthcare providers. The company operates laboratories that process specimens sent by hospitals, clinics, and other healthcare facilities. These services include cytogenetics (chromosome analysis), molecular diagnostics (genetic testing), and flow cytometry (cell analysis) - all specialized techniques used to diagnose and monitor blood cancers. The division has reached a breakeven point and generates approximately $4.5-4.9 million in quarterly revenue. **Products Division** (approximately 20-25% of revenue): This segment develops and sells proprietary diagnostic technologies and reagents to other laboratories. Key products include HemeScreen, a suite of genetic diagnostic panels specifically designed for blood cancer testing; IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four different blood cell types; and ICE-COLD PCR, a patented technology that increases the sensitivity of molecular-based tests. The products division generates approximately $700,000 in quarterly revenue and serves as a higher-margin, scalable business model.
Revenue model
Precipio generates revenue through two distinct business models that serve different market segments within the healthcare diagnostics ecosystem. The **pathology services division** operates on a fee-for-service model, where the company receives payment for each diagnostic test performed. Revenue comes from processing specimens sent by healthcare providers, with reimbursement typically coming from insurance companies, Medicare, Medicaid, and direct-pay patients. The company has recently received MolDx approval for next-generation sequencing testing, which could add approximately $250,000 in quarterly revenue through Medicare reimbursement. This division requires significant infrastructure investment in laboratory facilities, equipment, and specialized personnel, but provides steady recurring revenue as healthcare providers continue to send specimens for testing. The **products division** generates revenue through direct sales of diagnostic kits, reagents, and licensing of proprietary technologies to other laboratories and healthcare organizations. Customers include hospital laboratories, independent diagnostic laboratories, and biotechnology companies. This business model offers higher gross margins (approximately 51% versus 42% for pathology services) and greater scalability, as products can be manufactured and distributed without the per-unit labor costs associated with service delivery. The company leverages distribution partnerships with major healthcare distributors including Cardinal Health, ThermoFisher, and McKesson to reach customers. Several factors influence the company's margins and profitability. **Positive margin drivers** include increasing test volumes that leverage fixed laboratory costs, successful reimbursement approvals that improve payment rates, and the scalability of the products business which requires minimal incremental costs per sale. The company's proprietary technologies also provide some pricing power and differentiation. **Negative margin pressures** come from regulatory changes that can impact reimbursement rates, competition from larger diagnostic companies with greater resources, the need for continuous investment in new technologies and equipment, and the challenge of customer onboarding in the products division, where implementation delays can defer revenue recognition.
Competitive moat
Precipio's competitive moat is relatively narrow but developing, primarily built around proprietary technologies and specialized expertise rather than strong structural advantages. The company's main defensive positions include its patented ICE-COLD PCR technology, which increases the sensitivity of molecular diagnostics tests, and its specialized focus on blood cancer diagnostics where it has developed specific expertise and relationships. The **pathology services division** operates in a highly competitive market dominated by large players like Quest Diagnostics and LabCorp, which have significant advantages in scale, geographic reach, and reimbursement relationships. Precipio's competitive position here is primarily based on specialization in blood cancer testing and the ability to provide personalized service to smaller healthcare providers who may receive less attention from larger competitors. However, this specialization also limits the addressable market and provides minimal protection against well-funded competitors entering the space. The **products division** has stronger moat potential through its proprietary technologies and intellectual property. The HemeScreen panels and IV-Cell culture media represent differentiated products in the blood cancer diagnostics market, with the company estimating a $400 million total addressable market in the US. However, the company faces significant competitive threats from larger diagnostic companies with greater R&D budgets, established distribution networks, and stronger relationships with key customers. The company's moat is further weakened by its small size and limited financial resources compared to industry giants. Precipio lacks the scale to compete on price, the resources to fund extensive R&D, or the market presence to secure exclusive relationships with major healthcare systems. Regulatory changes, such as evolving FDA requirements for laboratory-developed tests, create additional uncertainty and compliance costs that disproportionately impact smaller companies. The company's survival and growth depend heavily on execution excellence and finding profitable niches that larger competitors may overlook.
Risks & safety
**Overall Assessment**: Precipio presents a moderate margin of safety with improving fundamentals but limited financial cushion. **Cash and Liquidity Position**: - Cash and short-term investments: $1.0 million (Q1 2025) - Current ratio: 0.76 (current liabilities exceed current assets) - Working capital deficit of approximately $1.1 million - Recently achieved positive cash flow from operations in Q4 2024 ($565K) and Q2 2024 ($500K) - Free cash flow turned positive in Q4 2024 ($521K) after years of negative performance **Debt and Solvency**: - Low debt-to-equity ratio of 0.18, indicating minimal debt burden - Total liabilities of $6.1 million against total assets of $17.8 million - No significant debt maturity concerns - Company approaching operational breakeven, reducing solvency risk **Valuation Metrics**: - Price-to-book ratio: 0.81 (trading below book value) - Market cap of approximately $17 million versus annual revenue of $16 million - Negative P/E ratio due to losses, but losses narrowing significantly - EV/EBITDA not meaningful due to minimal EBITDA **Other Considerations**: - Company achieved positive adjusted EBITDA in Q4 2024 for first time - 75% reduction in cash burn compared to prior year - Management expects return to positive cash flow in Q2 or Q3 2025 - Small float and limited liquidity create volatility risk
Recent development
Over the past few years, Precipio has undergone a significant strategic transformation from a cash-burning startup to a company approaching profitability and sustainability. The most notable development has been the **achievement of operational breakeven** in the pathology services division, which reached its target of $1.3 million in monthly revenue by Q3 2024 and has maintained that level through Q1 2025. The company has made substantial progress in **regulatory approvals and reimbursement**, most notably receiving MolDx approval for next-generation sequencing testing in early 2025, which is expected to add approximately $250,000 in quarterly revenue through Medicare reimbursement. Additionally, the FDA ruling on Laboratory Developed Tests was overturned in March 2025, providing regulatory relief for the company's testing services. **Product portfolio expansion** has been a key focus, with the launch of new diagnostic panels including a BCR-ABL assay developed for less than $100,000 and positioned in a $40 million annual revenue market. The company has expanded its HemeScreen portfolio to five different panels and continues to develop additional clinical diagnostic offerings. The products division has improved gross margins from 37% to 51% while maintaining steady revenue growth. **Commercial strategy enhancement** has included the hiring of Steve Miller as Chief Commercial Officer and strengthening distribution partnerships with major healthcare distributors including Cardinal Health, ThermoFisher, and McKesson. These partnerships provide access to over 250 sales representatives and significantly expand the company's market reach without proportional increases in sales costs. The company has also focused on **operational efficiency improvements**, reducing operating expenses as a percentage of revenue from 87% to 61% while maintaining quarterly operating expenses at approximately $3 million. Cash burn has been reduced by 75% compared to the prior year, and the company achieved positive cash flow from operations and free cash flow in Q4 2024. Management has transitioned from a "survival mindset" to a growth-oriented strategy, with plans to increase investor visibility and potentially provide formal guidance in 2025.
PRPO company profile · for informational purposes only — not investment advice.
Track PRPO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free